

**We are facing a world without
effective antibiotics-**

The urgent need for collective action

Otto Cars

Professor Infectious Disease, Uppsala University
Director, ReAct – Action on Antibiotic Resistance
Uppsala University, Sweden

www.reactgroup.org



***Antimicrobial* resistance or *Antibiotic* Resistance - a semantical confusion?**

Antimicrobial resistance (AMR)


```
graph TD; AMR[Antimicrobial resistance (AMR)] --- A[Antiviral agents (e.g. drugs for HIV)]; AMR --- B[Antiparasitic agents (e.g. drugs for malaria)]; AMR --- C[ABR]; C --- D[Antibacterial agents = Antibiotics (e.g. drugs for tuberculosis) and other bacterial diseases ...];
```

Antiviral
agents
(e.g. drugs
for **HIV**)

Antiparasitic
agents
(e.g. drugs for
malaria)

ABR


Antibacterial
agents = Antibiotics
(e.g. drugs for
tuberculosis)
and
***other bacterial
diseases ...***



**Patients with
pneumonia
and bacteria
in the blood**

**Penicillin
increased the
chance of survival
from 10% to 90%**

Adapted from Austrian *et al.*
Ann. Int. Med 1964; 60, 759



WHITewater: ANGUISH INSIDE THE WHITE HOUSE

Newsweek

March 28, 1994

\$2.95

ANTIBIOTICS

THE END OF MIRACLE DRUGS?

WARNING


NO LONGER
EFFECTIVE
AGAINST
KILLER
BUGS




Antibiotic resistance - a rhetorical problem ?

- Compared to other health problems, we are ***not*** talking about a specific disease
- Instead, we are talking about a medical product that is ***no longer working*** against bacteria causing ***many*** common infectious diseases

Common diseases- becoming non-treatable



In addition, many *medical procedures* are affected and threatened by ABR



Who is affected by ABR?

Everyone !

However

→... vulnerable populations with the highest infectious disease burden pays the highest price

→... these populations are also the ones that have least access to current and future interventions to manage antibiotic resistance

Some parts of the world have already run out of effective antibiotics



Muhimbili hospital, Dar es Salaam Tanzania

The mortality rate from Gram-negative bloodstream infection in children (43,5 %) was more than double that of malaria.

Blomberg et al. BMC Infect Dis. 2007



About 70% of neonatal systemic infections can not be treated with the antibiotics recommended by WHO....

Lancet 2005; 365: 1175–88

COST IMPLICATIONS OF GROWING ANTIBIOTIC RESISTANCE ARE HUGE

Typhoid fever

Cost of antibiotics for non-resistant cases	\$3-5
--	--------------

Cost of antibiotics for resistant cases

<i>Azithromycin</i>	\$35-42
---------------------	----------------

<i>Oral cephalosporins (cefixime)</i>	\$37-42
---------------------------------------	----------------

<i>Parenteral cephalosporins (ceftriaxone)</i>	\$84-104
--	-----------------

Average Treatment Costs for Typhoid (US\$)

Child weighing 20 kg using standard treatment guidelines

Source: AKU Pharmindex 2004 & WHO guidelines 2003

The MDG:s

- **Eradicate extreme poverty and hunger**
- **Achieve universal primary education**
- **Promote gender equality and empower women**
- **Reduce child mortality**
- **Improve maternal health**
- **Combat HIV/AIDS, malaria and other diseases**
- **Ensure environmental sustainability**
- **Develop a global partnership for development**

THE TIN

No. 68421 ■ THURSDAY JUNE 23 2005 ■ www.timesonline.co.uk ■ 55p



**m-seekers
nger protest**

Is of Zimbabwean
seekers in detention
egan a hunger strike
ain's decision to send
ck to face torture
bert Mugabe's regime.
age 3

cellor's call

Brown called on the
night to end its
onist ambitions and
e radical economic
needed to turn it from
oloc into a global force.
age 2

New strains of superbug hit hospitals

THE EXPRESS

THE NEWSPAPER FOR THE NEW MILLENNIUM

www.express.co.uk

FRIDAY NOVEMBER 5, 1999 (35p)



**At 65, she's the world's
most beautiful woman**

The incredible Sophia Loren • See Page 15

TRAVEL TO
EUROPE
FROM ONLY

£10

SEE
PAGE
56

HOSPITALS FEAR OVER SUPERBUG EPIDEMIC

**Vulnerable patients in danger from
deadly bacteria running riot on wards**

EXCLUSIVE BY ANTHONY DEVINS
AND RACHEL ELLIS

THE spread of a deadly superbug in British hospitals is reaching epidemic proportions, a leading scientist warned yesterday.

Over the past nine years, there has been a 13-fold increase in the incidence of the bug known as MRSA, which is resistant to all but the most powerful antibiotics.

In Scotland, Wales and the West Midlands, increases have been even more dramatic. Dr David Liver-

more, of the Public Health Laboratory Service, told The Express that the soaring number of cases was due to epidemic strains 15 and 16, particularly virulent forms of the bacteria which can be transmitted from patient to patient simply on the back of someone's hand.

Hospitals have been warned to step up infection control measures. Doctors and nurses are being reminded to wash their hands between patients, and GPs have been told to curb their prescribing of antibiotics, which only helps the bugs develop resistance. MRSA can be fatal, particularly to seriously ill

and elderly patients, but there are no official figures on the number of deaths caused by the bug and it is rarely identified as the cause on death certificates.

Potentially fatal blood poisoning caused by MRSA has increased from less than three per cent before 1991 to 37 per cent so far in 1999, Dr Livermore said.

"What we are talking about is this hospital bacteria that can cause serious infection, sometimes fatal - the deaths mostly in those who've got very severe underlying disease

TURN TO PAGE 4, COLUMN 1



**ONLY THIS DOG KNOWS
THE TRUTH ABOUT
GERI'S GINGER ROMANCE**

EXCLUSIVE INTERVIEW • SEE PAGE 3

WEATHER 2 • OPINION 10 • LETTERS 39 • DIARY 41 • LIFE 43-48 • CROSSWORD 58 • TV 61-65 • CITY 72-75

Burden of multidrug-resistant bacteria in the EU

Attributable deaths	approx.	25,000 / year
Extra hospital days	approx.	2.5 million / year
Total costs	approx.	€ 1.5 billion / year

Limitation: these are underestimates.

Burden of Antibiotic Resistance

Antibiotic resistance (ABR) poses an increasing threat to human health across the world. No country can escape from the medical and economic impacts from this serious problem.

Certain bacteria such as multi-resistant Gram-negative bacteria are particularly worrisome.¹ In the US, two thirds of deaths due to bacterial infections are caused by Gram-negative bacteria.²

Common diseases resulting from these bacteria are e.g. blood stream infections, urinary tract infections, post-operative wound infections and intra-abdominal infections.

The lack of effective antibiotics for treating these infections will increasingly lead to serious health problems and premature deaths.

The consequences of antibiotic resistance affect patients' lives but also

reaches far beyond the individual patient affecting health care systems and societies across the world.

Within just a few years, we may very well be faced with untreatable softbacks, medically, socially and economically unless we react now.

The ongoing pandemic spread of resistant bacteria illustrates that the problem can only be addressed through international cooperation.

The studies in this fact sheet were published between 2003 and 2012.

PATIENT GROUPS ESPECIALLY AFFECTED BY ABR

Newborns and children

- ESBL-producing bacteria are frequently causing infections in newborns. In an Indian hospital, *Klebsiella* and *E. coli* were the most common Gram-negative bacteria among infants with BSIs. About 33% of ESBL-infections were deadly in spite of available newer antibiotics and other supportive care.³

- In a study from Pakistan, 37 of 78 newborns (less than 30 days old) with infections due to *Acinetobacter* died within a short time frame. 71% of the bacteria were resistant to all antibiotics except polymyxins.⁴

- In an outbreak in India caused by NDM-1 *E. coli*, 4 newborn babies contracted blood stream infections (BSIs). All four died.⁵

- Three premature babies in a German neonatal ward died due to an outbreak of ESBL-producing *Klebsiella pneumoniae* from an unknown source.⁶

- In a study of Tanzanian children, the BSI rate was as high as 13.9%. One third of those children died. The death rate from Gram-negative BSI (43.3%) was more than double that of malaria (20.2%). One



© 2009 Uniqnet Rural, Mwanikya, Courtesy of P. Mwanikya

significant risk factor for death was treatment with ineffective antibiotics due to antibiotic resistance.⁷


Transplantation and cancer patients

- In Spain, among 416 patients undergoing transplantations of kidneys, 58 were infected with multi drug resistant (MDR) bacteria, most often Gram-negative. BSIs occurred in 14% of those. Death or graft

loss was significantly more frequent among those with MDR infections (19% vs. 8%).⁸

- In the US, an outbreak of *K. pneumoniae* carbapenemase-producing infections among liver transplant recipients killed two patients. A larger outbreak involving 24 patients soon followed the two initial cases in the ward.⁹

- In another study from the US, recent organ



How did we end up here?

- The indiscriminate use of antibiotics
- The rapid dynamics of gene transfer between bacteria and the global spread of resistance
- Poor sanitation and hygiene
- Alarming decline in antibiotics development





Illegal OTC antibiotic sale in the EU




**Athens, Greece 2008 (174 pharmacies)
2008:**

- 100% of all visited pharmacies sold Amoxicillin/clavulanate acid OTC
- 53% sold Ciprofloxacin OTC, despite extra restrictions for fluoroquinolone prescriptions





ESBL (CTX-M) producing *Enterobacteriaceae*

2001-2002



2007




THE DRUG DEVELOPMENT PIPELINE FOR ANTIBIOTICS HAS GONE DRY




THE DRUG DEVELOPMENT PIPELINE FOR ANTIBIOTICS HAS GONE DRY

- The last new antibiotic discovered in 1987 !
 - No new drugs for:**
 - Typhoid fever
 - Shigella
 - Gonorrhoea
 - Urinary tract infections
 - Blood infections
 -
 -
- The pipeline is drying up, with no new drugs coming to the market
- The pharmaceutical industry has lost interest in developing new antibiotics

We are facing a public health crisis



Strategies to stop manage antibiotic resistance



Prolong the lifespan of existing drugs

Rational Use

Better diagnostics

Prevent the spread of resistant bacteria

Improved hygiene

Infection control


Development of new antibiotics

New collaborative models

Controlled distribution and use of new future antibiotic

A new global system to preserve the effectiveness of antibiotics

Develop national action plans on antibiotic resistance !



Antibiotic Resistance

Caused by human activity and by over- consumption of a gobal resource

A failure of public policy & global governance, research prioritization and the current market system

It is a collective responsibility by governments, supranational organizations and individuals to take action



COMBAT DRUG RESISTANCE

**No action today,
no cure tomorrow**

